MYCN and neoplasm: MYCN amplification and ALK mutations promote tumor angiogenesis and vasculogenesis through the secretion of vascular endothelial cell growth factor (VEGF) by cancer cells and other cells residing in the TME, such as mesenchymal stromal cells (MSCs) and endothelial cells.